Upadacitinib in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Table 4

Subgroup analysis based on different dosage regimens (15 mg once daily or 30 mg once daily).

Characteristics	15 mg/d dosage group				30 mg/d dosage group				value
	Number of groups	Event rate (%)	I^2		Number of groups	Event rate (%)	I^2
EASI 50	2	79.1 (63.6–89.1)	67.654	0.079	3	87.6 (76.4–93.9)	46.365	0.155	0.266
EASI 75	7	64.3 (59.5–68.9)	46.872	0.080	8	75.3 (71.2–79.0)	53.785	0.034	<0.001
EASI 90	6	44.8 (41.7–47.9)	66.253	0.011	7	61.0 (58.3–63.5)	68.382	0.004	<0.001
EASI 100	4	14.0 (11.5–16.8)	20.397	0.288	6	29.0 (21.5–37.8)	88.189	0.000	<0.001
IGA 0/1	6	40.8 (36.5–45.2)	41.600	0.128	5	55.2 (49.8–60.4)	60.236	0.039	<0.001
Acne	6	10.4 (7.9–13.5)	42.362	0.123	7	15.5 (13.6–17.5)	2.491	0.406	0.007
Nasopharyngitis	5	9.4 (6.7–12.9)	57.441	0.052	6	9.6 (6.8–13.5)	73.332	0.002	0.906
URTI	4	7.9 (6.3–9.8)	0.000	0.569	5	8.8 (7.3–10.6)	70.095	0.010	0.734
Blood CPK increased	5	4.9 (3.7–6.6)	1.288	0.399	5	5.9 (4.7–7.4)	0.000	0.609	0.325

URTI, upper respiratory tract infection; CPK, creatine phosphokinase.